Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Testosterone Clear all
Recruiting Phase 2 Interventional

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

NCT05011383
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
High dose testosterone
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
17
States / cities
Aurora, Colorado • West Haven, Connecticut • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331123
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy

NCT00245518
View directory record Official record
Conditions
Hot Flashes
Interventions
Isoflavone, Placebos
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 2, 2026, 2:22 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD

NCT03674320
View directory record Official record
Conditions
COPD
Interventions
Testosterone Enanthate, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 4 Interventional

Effect of Testosterone Replacement on Insulin Resistance

NCT00487734
View directory record Official record
Conditions
Metabolic Syndrome, Hypogonadism
Interventions
Testosterone gel, Placebo for testosterone gel
Radiation · Drug
Lead sponsor
McGuire Research Institute
Other
Eligibility
20 Years to 65 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone

NCT00839319
View directory record Official record
Conditions
Healthy Males
Interventions
Acyline, placebo hCG (no active ingredient), hCG (human chorionic gonadotropin), Testosterone gel
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 2, 2026, 2:22 PM EDT
Active, not recruiting Not applicable Interventional

Evaluating the Influence of Diet-induced Weight Loss on Fat (Adipose) Tissue's Insulin Sensitivity and Testosterone Synthesis in Women With Overweight or Obesity, Insulin Resistance, and Hyperandrogenemia

NCT06998238
View directory record Official record
Conditions
Overweight and Obesity, Hyperandrogenemia, Insulin Resistance
Interventions
Mediterranean-based, carbohydrate restricted, calorie reduced diet
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

NCT01386606
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal (enclomiphene citrate), Testosterone
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

NCT02013544
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, Prasterone (DHEA)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations

NCT00857961
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone MD-Lotion
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Tuscon, Arizona • Burbank, California • New Britain, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Sep 2, 2026, 2:22 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading

NCT01763541
View directory record Official record
Conditions
Hypertension
Interventions
leuprolide acetate, Anastrozole
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

NCT00962637
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal, AndroGel, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 68 Years · Male only
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

NCT05081193
View directory record Official record
Conditions
Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone Undecanoate, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 4 Interventional Results available

AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment

NCT00304746
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Testosterone gel, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
30 Years to 65 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction

NCT00755183
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
testosterone ophthalmic solution, vehicle of testosterone ophthalmic solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 2, 2026, 2:22 PM EDT
Withdrawn Phase 3 Interventional

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study

NCT03619005
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Interventions
Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Huntsville, Alabama • San Diego, California • New London, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal Women

NCT00224094
View directory record Official record
Conditions
Menopause
Interventions
Premarin® (oral) vs. Alora® (transdermal)
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
42 Years to 70 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 2Phase 3 Interventional

Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention

NCT00189124
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Dehydroepiandrosterone (DHEA)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue

NCT00490555
View directory record Official record
Conditions
Healthy
Interventions
Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA), Placebo Testosterone gel, Placebo dutasteride, Placebo DMPA
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Sep 2, 2026, 2:22 PM EDT
Completed No phase listed Observational

Data Mining: Precision Analytical Retrospective Data Correlation

NCT04305093
View directory record Official record
Conditions
Obesity; Endocrine, Hormone Disturbance
Interventions
Not listed
Lead sponsor
Precision Analytical, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
144,561 participants
Timeline
2019 – 2023
U.S. locations
1
States / cities
McMinnville, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 2, 2026, 2:22 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

The Effect of 5-Alpha Reductase on Testosterone in Men

NCT00070733
View directory record Official record
Conditions
Sex Disorders
Interventions
testosterone enanthate, duastride
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years to 40 Years · Male only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2005 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 2 Interventional

Dehydroepiandrosterone Effects on HIV-1 Replication

NCT00065104
View directory record Official record
Conditions
HIV Infections
Interventions
DHEA
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2006 · Synced Sep 2, 2026, 2:22 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®

NCT01096329
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 2, 2026, 2:22 PM EDT
Completed Phase 2 Interventional

28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men

NCT00398580
View directory record Official record
Conditions
Hypogonadism, Hypogonadism, Male
Interventions
Nanomilled testosterone, Nanomilled dutasteride, commercially available dutasteride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Torrance, California • Louisville, Kentucky • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 2, 2026, 2:22 PM EDT